AEMD - Aethlon Medical, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.0400
-0.9600 (-48.00%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.0000
Open1.1200
Bid1.0200 x 1000
Ask1.0300 x 2200
Day's Range1.0000 - 1.1200
52 Week Range1.0000 - 25.6500
Volume3349538
Avg. Volume70,228
Market Cap1.5M
Beta (5Y Monthly)0.42
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • PR Newswire

    Aethlon Medical Announces Pricing of $5 Million Public Offering

    Aethlon Medical, Inc. (Nasdaq:AEMD) (the "Company"), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced the pricing of an underwritten public offering of 3,333,334 shares of common stock (which includes pre-funded warrants to purchase shares of common stock in lieu thereof), and common warrants to purchase up to an aggregate of 3,333,334 shares of common stock at a public offering price of $1.50 per share. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with a common warrant to purchase one share of common stock. The common warrants have an exercise price of $1.50 per share, are immediately exercisable, and will expire five years from the date of issuance. The Company has granted the underwriter a 45-day option to purchase up to an additional 499,999 shares of common stock and/or common warrants to purchase up to 499,999 shares of common stock, at the public offering price, less underwriting discounts and commission.

  • PR Newswire

    Aethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update

    SAN DIEGO , Nov. 1, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, ...

  • PR Newswire

    Aethlon Medical To Release Second Quarter Financial Results and Host Conference Call on November 1, 2019

    SAN DIEGO, Oct. 29, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its second quarter fiscal year 2020, ended September 30, 2019, at 4:15pm Eastern time on Friday, November 1, 2019. Management will host a conference call on Friday, November 1, 2019 at 4:30pm Eastern time to review financial results and recent corporate developments. To listen to the call by phone, interested parties within the U.S. should call 1-844-836-8741 and International callers should call 1-412-317-5442.

  • PR Newswire

    Aethlon Announces Reverse Stock Split

    SAN DIEGO, Oct. 14, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD) ("Aethlon" or the "Company"), a therapeutic medical device and technology company focused on unmet needs in global health, announced today that at the annual meeting of stockholders of the Company, held October 14, 2019, its stockholders voted to approve a proposal authorizing the Board of Directors of the Company to effect a reverse stock split of Aethlon's outstanding common stock. Following the special meeting of stockholders, the Board of Directors approved a 1-for-15 reverse stock split.

  • PR Newswire

    Aethlon Medical Announces FDA Approval Of IDE For Oncology Indications

    SAN DIEGO, Oct. 7, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic medical device and technology company focused on unmet needs in global health, announced today that the FDA has approved its Investigational Device Exemption (IDE) application to initiate an Early Feasibility Study (EFS) of the Company's proprietary Hemopurifier® in patients with head and neck cancer in combination with standard of care pembrolizumab (Keytruda).

  • PR Newswire

    Aethlon Medical Receives Extension from Nasdaq to Regain Compliance with Continued Listing Requirements

    SAN DIEGO, Oct. 3, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health, announced today that on October 2, 2019, Nasdaq granted Aethlon Medical an extension of time to regain compliance with the exchange's continued listing requirement of a minimum $2.5 million of stockholders' equity. This extension is conditional upon Aethlon Medical completing a reverse stock split and trading at or above Nasdaq's minimum $1.00 bid price requirement for a period of ten consecutive trading days on or before October 29, 2019. The Company is requesting stockholder approval of the reverse stock split at its Annual Meeting of Stockholders to be held on October 14, 2019 in order to meet this requirement.

  • Aethlon Announces Collaboration to Identify Exosomes Involved in Cancer Progression and Treatment Resistance
    PR Newswire

    Aethlon Announces Collaboration to Identify Exosomes Involved in Cancer Progression and Treatment Resistance

    SAN DIEGO, Sept. 24, 2019 /PRNewswire/ -- EXOSOME SCIENCES, a subsidiary of Aethlon Medical, Inc. (AEMD), announced a research collaboration to identify and characterize exosomes derived from patients with solid tumors such as pancreas cancer, as well as from families with genetically high risk of developing cancer.  These cancer-derived exosomes may serve as early markers for cancer diagnostics, cancer progression and treatment resistance. Exosome Sciences, Inc., a majority owned subsidiary of Aethlon Medical, Inc., is a diagnostic company focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disease progression.

  • PR Newswire

    Aethlon Medical Receives National Cancer Institute Contract Award

    SAN DIEGO, Sept. 16, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health, announced today that the National Cancer Institute (NCI) has awarded the Company an SBIR Phase 2 contract for Topic 359, a solicitation entitled "Technologies for Differential Isolation of Exosomes and Oncosomes." This solicitation prioritized the advancement of technologies for isolating exosomes from biofluids for applications in oncology research and clinical care. Exosomes are nanoparticles that are abundantly released from cancer cells and carry the complement of a tumor's genetic and protein cargo, making them important targets for non-invasive liquid biopsies in cancer. Aethlon is actively developing assays in this area through its majority-owned subsidiary, Exosome Sciences, Inc. However, there remains a need for high-throughput and selective technologies which isolate exosomes from various bodily fluids that could be adopted in clinical workflows.

  • PR Newswire

    Aethlon Medical Announces First Quarter Financial Results and Provides Corporate Update

    SAN DIEGO , Aug. 14, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, today reported financial results for its first ...

  • PR Newswire

    Aethlon Medical To Release First Quarter Financial Results and Host Conference Call on August 14, 2019

    SAN DIEGO, Aug. 7, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health, today announced that it will issue financial results for its first quarter fiscal year 2020, ended June 30, 2019, at 4:15pm Eastern time on Wednesday, August 14, 2019. Management will host a conference call on Wednesday, August 14, 2019 at 4:30pm eastern time to review financial results and recent corporate developments. To listen to the call by phone, interested parties within the U.S. should call 1-844-836-8741 and International callers should call 1-412-317-5442.

  • PR Newswire

    Aethlon Medical Announces Fiscal Year End Financial Results and Provides Corporate Update

    SAN DIEGO , July 1, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, today reported financial results for its fiscal ...

  • ACCESSWIRE

    Aethlon Medical, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 1, 2019 / Aethlon Medical, Inc. (NASDAQ: AEMD ) will be discussing their earnings results in their 2019 Fourth Quarter Earnings to be held on July 1, 2019 at 4:30 PM Eastern ...

  • PR Newswire

    Aethlon Medical, Inc. and SeaStar Medical, Inc. Announce Strategic Joint Cross-Licensing Agreement

    SAN DIEGO and CARDIFF, Calif., July 1, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD) and SeaStar Medical, Inc. today announced a cross-licensing agreement to jointly develop their respective medical devices to address the care and management of critically ill patients. Aethlon Medical is developing the Hemopurifier®, a first-in-class blood purification cartridge used to remove a range of different particles from the blood, including cancer promoting exosomes for the treatment of cancers with no adequate alternative therapy and viruses for the treatment of life-threatening viral diseases. SeaStar's platform of cartridges include the CLR 2.0 Hemofilter which is FDA 510K cleared for acute kidney injury (AKI), congestive heart failure (CHF) and pulmonary edema and is currently being marketed for organ preservation in the solid organ transplant market.  Each company's cartridges are designed to fit onto standard, hospital ICU-based equipment, either independently or together, and the companies plan to jointly develop complete treatment solutions that will allow deployment into multiple inpatient and outpatient treatment settings in any clinical indication where combined use of the Hemopurifier and CPCs may improve or expand indications for use, including but not limited to infectious disease, oncology and organ preservation and transplant.

  • PR Newswire

    Aethlon Medical To Release Fiscal Year End Financial Results and Host Conference Call on July 1, 2019

    SAN DIEGO, June 19, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health, today announced that it will issue financial results for fiscal year 2019, ended March 31, 2019, at 4:15pm Eastern time on Monday, July 1, 2019. Management will host a conference call on Monday, July 1, 2019 at 4:30pm eastern time to review financial results and recent corporate developments. To listen to the call by phone, interested parties within the U.S. should call 1-844-836-8741 and International callers should call 1-412-317-5442.

  • PR Newswire

    Aethlon Medical Announces Collaboration With Prostate On-Site Project (POP), Host Of The Jerry Colangelo Sports Legend Golf Classic, To Engage With Participants For CTE Studies

    PHOENIX, May 13, 2019 /PRNewswire/ -- Aethlon Medical Inc. (AEMD) and its diagnostic subsidiary, Exosome Sciences, in collaboration with the Translational Genomics Research Institute (TGen) and the Prostate On-Site Project (POP), announced that Aethlon, TGen and POP will engage with participants for their studies of chronic traumatic encephalopathy (CTE) in living individuals during the 18th annual Jerry Colangelo Sports Legends Golf Classic in Phoenix. Study participants will include former athletes who may have experienced repeated head impacts, such as former NFL players, as well as controls, those who played sports such as baseball that usually do not have significant head impacts.

  • Aethlon Medical Releases Shareholder Update
    PR Newswire

    Aethlon Medical Releases Shareholder Update

    SAN DIEGO, April 17, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), today released the following shareholder update authored by its CEO, Timothy C. Rodell, M.D. With Chuck and the board's support and advice, our team is now working on executing a plan to advance Aethlon's unique Hemopurifier through clinical trials and regulatory approvals, toward ultimate commercialization as quickly and efficiently as possible.  This process should be accelerated by the FDA's designation of the Hemopurifier as a "Breakthrough Device" for both viral diseases and cancer.

  • PR Newswire

    Aethlon Medical, Inc. Announces Appointment of Lisa M. Boswell as Director, Quality Systems and Regulatory Affairs

    SAN DIEGO, March 7, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic medical device company focused on addressing critical unmet needs in global health, announces the appointment of Lisa M. Boswell, to the position of Director, Quality Systems and Regulatory Affairs.  Ms. Boswell has over 15 years of experience in Quality Control, Quality Assurance and Regulatory Affairs in both the biopharmaceutical and medical device industries, most recently as Director, Quality Assurance and Regulatory Affairs at ZOLL Data Systems, Inc.

  • PR Newswire

    Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update

    SAN DIEGO , Feb. 11, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, today reported financial results for the third ...

  • PR Newswire

    Aethlon Medical To Release Quarterly Financial Results and Host Conference Call on February 11, 2019

    SAN DIEGO, Feb. 4, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health, today announced that it will issue financial results for the third quarter of fiscal year 2019, ended December 31, 2018, at 4:15 pm eastern time on Monday, February 11, 2019. Management will host a conference call on Monday, February 11, 2019 at 4:30 pm eastern time to review financial results and recent corporate developments. International callers should call 1-412-317-5442.

  • GlobeNewswire

    Market Trends Toward New Normal in Roper Technologies, The AES, D.R. Horton, Forrester Research, Aethlon Medical, and CyberOptics — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Jan. 18, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.